CompletedPhase 4

Management of Superficial Thrombophlebitis

United States72 participantsStarted 2002-10

Plain-language summary

The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with confirmed upper or lower extremity superficial thrombophlebitis by ultrasound imaging Exclusion Criteria: * Active, clinically significant bleeding * Known hypersensitivity to NSAIDS, heparin or derivatives * Currently pregnant or \< 1 week post-partum * Acquired bleeding diathesis * Known inherited bleeding disorder * Renal failure * Extremes of weight * unable to return for repeat diagnostic testing or follow-up visit * Concurrent deep-vein thrombosis

What they're measuring

Thrombosis Progression and Venous Thromboembolism (VTE)

Timeframe: Day 14

Thrombosis Progression or Venous Thromboembolism (VTE) at 3 Months

Timeframe: 3 months

Trial details

NCT IDNCT00264381

SponsorUniversity of Oklahoma

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-09

Results submitted2013-11-14

View on ClinicalTrials.gov More Superficial Thrombophlebitis trials